BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib)
BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysisBRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ETCAMBRIDGE, Mass. & BEIJING--(BU...
Source: pharmiweb.com